| The following article features coverage from the 2020 Genitourinary Cancers Symposium meeting. Click here to read more of Renal and Urology News’ conference coverage. |
SAN FRANCISCO—Bone metastases already present at the time of cytoreductive radical nephrectomy for metastatic renal cell carcinoma (mRCC) do not portend worse survival or oncologic outcome, investigators reported at the 2020 Genitourinary Cancers Symposium.
“The prognostic significance of bone metastases may be less than previously hypothesized,” Aaron Bradshaw, BS, of the University of California San Diego Health, La Jolla, told Renal & Urology News.
Continue Reading
Of 447 mRCC patients from the Registry of MetAstatic RCC (REMARCC) database, 124 had bone metastases and 323 did not. In Kaplan Meier analyses, the investigators found no significant difference in progression-free survival (PFS; 6.1 vs 6.4 months, respectively) or overall survival (OS; 25.5 vs 26.5 months, respectively) between groups.
When the investigators further stratified patients by Memorial Sloan Kettering Cancer Center/Motzer low-, intermediate-, and high-risk categories, they likewise found no significant differences between the bone metastases and no-bone metastases groups in either PFS or OS.
Multivariate analyses for PFS and OS demonstrated worsening prognosis as risk category increased from low to intermediate to high, as expected.
“This study suggests the presence of bony metastases are not independently predictive of worsened survival in patients with metastatic renal cell carcinoma,” Bradshaw stated. “These findings can reasonably be incorporated into the individual prognostication process for patients with metastatic disease.”
Read more of our coverage of the 2020 Genitourinary Cancers Symposium by visiting the conference page.
Reference
Bradshaw A, Mir MC, Autorino R, et al. Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database. Presented at the 2020 Genitourinary Cancers Symposium held February 13 to 15 in San Francisco. Poster and abstract 655.
